On May 23, 2024, Evaxion Biotech A/S agreed to amend their Series A Warrants, changing the exercise price from $4.00 to 27.52 DKK per American Depositary Share (ADS). This involves 3,750,000 ADSs representing 37,500,000 ordinary shares, and there will be a 60-day period during which no new ADSs can be issued without certain exceptions.